Carregant...
Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
BACKGROUND: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patient...
Guardat en:
| Publicat a: | Drugs Context |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioExcel Publishing Ltd
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8152773/ https://ncbi.nlm.nih.gov/pubmed/34104197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2021-2-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|